Sugi Predict

Sugi Predict / Compounds / SCHEMBL29620290

SCHEMBL29620290

SCHEMBL29620290

Cc1cc(C)c(N2CCN(c3c(C)cc(C)cc3C)C2=[Ru-4](Cl)(Cl)=Cc2cc([N+](=O)[O-])ccc2OC(C)C)c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.36
▸ DRD2 P14416 1/20 0.33
▸ ADRA1D P25100 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ ADRA1B P35368 1/20 0.33
▸ MAPT P10636 3/20 0.33
▸ GAA P10253 2/20 0.33
▸ TDP1 Q9NUW8 4/20 0.32
▸ ALDH1A1 P00352 5/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ PDK1 Q15118 1/20 0.32
▸ CCR5 P51681 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TSHR P16473 2/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ POLB P06746 2/20 0.31
▸ THRB P10828 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29860852 0.89 CYP19A1 (0.35) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL29860689 0.85 CYP19A1 (0.35) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL29860905 0.85 MAPK1 (0.38) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL31546449 0.84 CYP19A1 (0.40) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL29814403 0.84 POLB (0.35) LMNASMN1; SMN2POLBL3MBTL1
SCHEMBL1194744 0.83 CYP19A1 (0.35) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL29380873 0.83 CYP19A1 (0.35) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL17801510 0.83 CYP19A1 (0.36) CYP19A1DRD2ADRA1DADRA1AADRA1B
Hydrochloric Acid SCHEMBL28414018 0.82 CYP19A1 (0.36) CYP19A1DRD2ADRA1DADRA1AADRA1B
SCHEMBL29381375 0.82 MAPT (0.34) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4367109-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES Firmenich SA (CH) 2024-05-15 — — EP claimed
CN-117916227-A Process for preparing perfuming intermediates 弗门尼舍有限公司 2024-04-19 — — CN claimed
WO-2023036732-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES FIRMENICH SA (CH) 2023-03-16 — — WO claimed
CN-115003649-A Process for the preparation of perfuming intermediates 弗门尼舍有限公司 2022-09-02 — — CN claimed
EP-4737444-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2026-05-06 — — EP disclosed
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2025-06-05 — — US disclosed
WO-2025105486-A1 ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE 第一三共株式会社 2025-05-22 — — WO disclosed
EP-4525986-A1 SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION Vertex Pharmaceuticals Incorporated (US) 2025-03-26 — — EP disclosed
US-12202782-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-01-21 — — US disclosed
EP-4484435-A2 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2025-01-01 — — EP disclosed
EP-4065567-B1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES INC (US) 2024-09-11 — — EP disclosed
US-20230013713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2023-01-19 — — US disclosed
EP-4069667-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATE Firmenich SA (CH) 2022-10-12 — — EP disclosed
EP-4065567-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-05 — — EP disclosed
CN-115003649-A Process for the preparation of perfuming intermediates 弗门尼舍有限公司 2022-09-02 — — CN disclosed
EP-4009966-A1 SCALEABLE PREPARATION OF POLYKETIDES The Regents of the University of California (US) 2022-06-15 — — EP disclosed
US-20220177409-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2022-06-09 — — US disclosed
WO-2022108984-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-05-27 — — WO disclosed
US-11325891-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2022-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 CYP19A1 4443/4885DRD2 4717/4885ADRA1D 4493/4885
US-20220177409-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BCL3, XIAP CYP19A1 3608/4885DRD2 4716/4885ADRA1D 4702/4885
US-12202782-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BCL3, XIAP CYP19A1 3608/4885DRD2 4716/4885ADRA1D 4702/4885
US-11325891-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 CYP19A1 4443/4885DRD2 4717/4885ADRA1D 4493/4885
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BCL3, XIAP CYP19A1 3608/4885DRD2 4716/4885ADRA1D 4702/4885
US-20230013713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BAK1, BCL3 CYP19A1 4443/4885DRD2 4717/4885ADRA1D 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.